WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study